Spravato REMS Program Requirements for Providers in 2026

Spravato treatment must take place through a certified healthcare setting, with the medicine administered under direct observation and at least two hours of monitoring afterward. For patients and families, the practical meaning is simple: a clinic should be able to explain its Spravato Risk Evaluation and Mitigation Strategy, or REMS, workflow before you schedule, including who monitors you, how you get home, and what happens if you feel unwell.

Spravato is the brand name for esketamine nasal spray, a prescription medicine that the U.S. Food and Drug Administration, or FDA, has approved for certain adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, when used with an oral antidepressant. This differs from racemic ketamine, which is prescribed off-label for depression and most mental-health uses. Treatment decisions should be made with a licensed clinician who can review your diagnosis, medical history, current medicines, and safety needs.

In 2026, REMS requirements are a meaningful way to compare Spravato providers. They do not guarantee that a clinic is the right fit, but they set a federally required structure around dispensing, observation, and follow-up that an ordinary prescription pickup does not provide.

What the Spravato REMS requires from providers

The Spravato REMS is an FDA-required safety program designed to manage risks of sedation, dissociation, respiratory depression, abuse, and misuse. A REMS is a drug-safety program the FDA can require when labeling alone is not considered sufficient to manage known serious risks.

According to the FDA-approved Spravato prescribing information, treatment must be administered under the direct observation of a healthcare provider, followed by monitoring for at least two hours. The same document states that Spravato is available only through the REMS program and must not be dispensed directly to patients for home use.

• Healthcare settings must enroll and be certified in the REMS program.
• Prescribers must enroll and complete REMS requirements before prescribing Spravato.
• Pharmacies must be certified and dispense Spravato only to certified healthcare settings.
• Patients must be enrolled before treatment, and the setting must document required monitoring and counseling steps.

A patient does not need to audit a clinic's paperwork. You can, however, ask the clinic to describe these steps in plain language. A clear answer is a useful sign that the care team has a repeatable process rather than treating monitoring as an afterthought.

Why monitoring changes the provider comparison

Spravato can cause sleepiness, dissociation, and temporary increases in blood pressure. Dissociation is a change in perception or sense of connection to yourself or your surroundings. These effects are why a certified setting needs space, trained staff, a monitoring plan, and a clear procedure for responding if your recovery takes longer than expected.

The FDA label says patients should not drive or operate machinery until the next day after a restful sleep. That makes transportation part of treatment planning, not a minor logistical detail. Ask whether the clinic requires a designated ride, permits rideshare pickup, and has a procedure if your ride is delayed.

REMS certification is only one layer of quality. You should also understand ketamine provider safety protocols what to verify before treatment, including how the team screens for medical concerns, measures vital signs, and handles urgent changes during a visit. A clinic should also be able to explain how ketamine providers handle adverse reactions during treatment without making you feel rushed or embarrassed for asking.

Who a Spravato clinic may suit, and who may need another conversation

A REMS-certified Spravato provider may suit someone whose clinician believes the FDA-approved indication fits, who can attend repeated in-person visits, and who can arrange transportation after each session. It may be less practical for someone who cannot reliably get to a certified site, cannot arrange a safe ride home, or needs a care plan that the clinic cannot coordinate with their existing mental-health team.

Do not assume that FDA approval means the treatment is appropriate for every form of depression. The evidence and approved uses are specific. The FDA-approved label describes Spravato's indicated populations, contraindications, monitoring requirements, and adverse reactions. Your prescriber should explain why the treatment is being considered in your situation, what alternatives are reasonable, and how progress will be judged.

Continuity matters because treatment is more than a monitored appointment. Ask about communication with your psychiatrist, therapist, primary-care clinician, or other prescribers. These questions to ask about a ketamine provider's continuity of care can help you identify who owns follow-up, medication coordination, and support if your symptoms change between visits.

Costs, insurance, and the questions that prevent surprises

Spravato care is usually billed as several parts, not one simple medication price: the medicine, the observed administration visit, the monitoring time, and related evaluation or follow-up services. Your out-of-pocket cost can vary based on insurance coverage, deductible status, network participation, treatment frequency, and whether the clinic bills separate facility or professional fees. Ask for a written estimate based on your insurance before committing to a series of appointments.

Medicare, Medicaid, and commercial plans can have different prior-authorization and site-of-care rules. A clinic can help submit information, but it cannot promise coverage. Ask which parts of the treatment estimate are confirmed by your insurer, which are estimates, and what you would owe if authorization is denied or changed.

Practical safety questions still matter alongside billing. Read about what makes a ketamine clinic safe before comparing locations, and review ketamine therapy follow up appointments to understand what ongoing care can look like. If a provider cannot give a clear answer about costs, monitoring, or follow-up, pause before scheduling and seek clarification.

Use REMS as a starting point, not the final decision

The best question is not only whether a provider is REMS-certified. It is whether the clinic can show you how certification becomes safe, coordinated care in the room: clear screening, calm monitoring, a practical departure plan, transparent billing, and follow-up that does not end when you leave the office.

Bring a family member or support person into the decision if you can. They may notice gaps in transportation planning, cost explanations, or communication that are easy to miss when you are focused on whether treatment might help. This article is educational information, not medical advice. Discuss whether Spravato or another treatment approach is appropriate for you with a licensed clinician.